Experimental Drug May STOP Deadly Genetic Death Sentence

Illustration of a DNA double helix on a blue background — DEADLY GENETIC DISEASE BOMBSHELL

A 41-year-old scientist is defying a family curse that has killed relatives across five generations by becoming the first person to receive an experimental gene-silencing drug before ALS symptoms appeared.

Story Snapshot

Jeff Vierstra carries a lethal FUS gene mutation that killed his mother at age two for him and claimed aunts and sisters in their 30s and 40s from aggressive ALS
He began presymptomatic treatment with ulefnersen in 2020, receiving spinal infusions every few months to silence the toxic protein before disease onset
After three years of treatment, his muscle electrical activity normalized and he remains symptom-free, outliving family members who started treatment after symptoms appeared
His sisters Erin and Leigh died after enrolling in the same trial, but their symptomatic treatment came too late to halt neurological damage already underway
The approach represents a paradigm shift toward preventing neurodegenerative diseases rather than merely slowing their progression once symptoms emerge

When Death Comes Early and Often in Your Family Tree

Jeff Vierstra grew up knowing his family carried a death sentence. His mother succumbed to ALS when he was just two years old, lasting only nine months after diagnosis. Genealogical records revealed a haunting pattern stretching back to the 1800s: relatives dying in their 30s and 40s from a mysterious paralytic illness.

By the 2010s, the genetic culprit emerged as a mutation in the FUS gene, causing an exceptionally aggressive form of amyotrophic lateral sclerosis that destroys motor neurons with ruthless efficiency.

When Vierstra and his sisters tested positive for the mutation, they faced statistical certainty. With familial ALS comprising roughly ten percent of cases and FUS mutations accounting for a small fraction of those, their variant represented one of the disease’s cruelest expressions.

Unlike typical ALS, which grants patients an average survival of two to five years post-diagnosis, FUS-ALS accelerates the timeline, ravaging bodies and minds faster than most treatments can intervene.

A Chance Meeting That Changed Everything

The 2018 ALS conference in Barbados proved pivotal for Vierstra. There he encountered Dr. Neil Shneider from Columbia University’s Eleanor and Lou Gehrig ALS Center, who had published promising research in Nature Medicine demonstrating that an antisense oligonucleotide called ulefnersen could silence the mutant FUS gene in mice.

The drug worked by targeting the RNA instructions that produce the toxic protein, effectively turning down the volume on a deadly genetic command.

Shneider’s team had secured FDA approval for expanded access, allowing compassionate use outside traditional clinical trials. By summer 2020, Vierstra and his sisters Erin and Leigh enrolled. The sisters had already developed symptoms, their muscles weakening as motor neurons died.

Vierstra, however, remained asymptomatic despite abnormal electromyography readings suggesting subclinical nerve damage. This distinction between presymptomatic and symptomatic treatment would prove decisive in the years ahead.

The Divergent Paths of Three Siblings

Ulefnersen arrives via intrathecal injection, delivering the drug directly into spinal fluid where it can reach motor neurons before they degenerate beyond rescue. For Erin and Leigh, the treatment appeared to extend life, though both ultimately succumbed—Erin to ALS progression after three years, Leigh to an unrelated head injury after four.

Their experiences, while tragic, provided crucial data. An autopsy on the trial’s first patient confirmed the drug reduced FUS protein levels without detectable side effects.

Vierstra’s trajectory diverged dramatically. Within one year of starting treatment, his electromyography normalized, indicating that muscle electrical activity had returned to healthy parameters.

He continues receiving infusions every few months, maintains an active lifestyle including skiing and skydiving, and at 41 has outlived the age at which most family members developed symptoms. His case suggests that intervention before irreversible neurological damage occurs may fundamentally alter disease outcomes.

What Science Learns from One Man’s Survival

The broader implications extend beyond a single family’s struggle. Columbia’s Silence ALS initiative now explores personalized gene therapies for more than twenty ALS-related mutations, potentially transforming how medicine approaches the ten percent of cases with hereditary origins.

Data from the first twelve patients published in May 2025 confirmed FUS protein reduction across participants, validating the mechanism Shneider’s team pioneered in animal models years earlier.

Ionis Pharmaceuticals, which developed ulefnersen, continues sponsoring trials that could eventually secure formal FDA approval beyond compassionate access. The success here validates antisense oligonucleotide technology for central nervous system disorders, a platform already yielding other neurological treatments.

For the thirty thousand Americans living with ALS and the five thousand newly diagnosed annually, the Vierstra case offers something scarce in neurodegenerative disease research: tangible hope grounded in measurable biomarker improvements.

Scientist whose mother and sisters died of ALS complications hopes experimental treatment will save his life https://t.co/9PQCDmuZYL

— CBS News (@CBSNews) April 5, 2026

Vierstra himself remains cautiously optimistic, acknowledging that long-term efficacy remains unproven beyond his normalized electromyography and symptom-free status. He can now contemplate a future his mother, aunts, and sisters never experienced. Whether this treatment truly breaks the generational curse or merely delays the inevitable requires more time and data.

Yet the principle stands: attacking genetic diseases before symptoms manifest may represent medicine’s most promising frontier, transforming fatal diagnoses into manageable conditions through proactive intervention rather than reactive palliation.